Alzheimer's Disease News and Research RSS Feed - Alzheimer's Disease News and Research Twitter

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
New in vitro system could become important tool in search for potential drugs against Alzheimer’s

New in vitro system could become important tool in search for potential drugs against Alzheimer’s

A typical characteristic of the brain of an Alzheimer sufferer is the presence of insoluble Tau protein aggregates. Scientists at VIB, KU Leuven and Janssen Pharmaceutica have demonstrated that the distribution of these aggregates through the brain is facilitated by synaptic connections between brain cells. [More]
Previous motherhood alters cognition, neuroplasticity in response to hormone therapy

Previous motherhood alters cognition, neuroplasticity in response to hormone therapy

Hormone therapy (HT) is prescribed to alleviate some of the symptoms of menopause in women. Menopausal women are more likely to be diagnosed with Alzheimer's disease but not other forms of dementia, and HT has been prescribed to treat cognitive decline in post-menopausal women with variable degrees of effectiveness. [More]
Mayo Clinic scientists create mouse model of ALS, FTD caused by mutations in C9ORF72 gene

Mayo Clinic scientists create mouse model of ALS, FTD caused by mutations in C9ORF72 gene

Scientists at Mayo Clinic, Jacksonville, Florida created a novel mouse that exhibits the symptoms and neurodegeneration associated with the most common genetic forms of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), both of which are caused by a mutation in the a gene called C9ORF72. [More]
Decreased removal of toxic peptides causes onset of Alzheimer's disease

Decreased removal of toxic peptides causes onset of Alzheimer's disease

Jens Pahnke and his team at the University of Oslo has recently published results in the prestigious scientific journal 'BRAIN' showing that decreased removal of toxic peptides in the brain causes the onset and first clinical signs of Alzheimer's disease, rather than overproduction as has previously been assumed. This information can now be used to target specific genes to enhance their function in the brain of elderly or people at risk. [More]
Certain proteins may slow cognitive decline in people with Alzheimer's disease

Certain proteins may slow cognitive decline in people with Alzheimer's disease

Certain proteins may slow the devastating memory loss caused by Alzheimer's disease, according to a groundbreaking Iowa State University study. [More]
Available research does not support link between chronic traumatic encephalopathy and sports

Available research does not support link between chronic traumatic encephalopathy and sports

Available research does not support the contention that athletes are uniquely at risk of chronic traumatic encephalopathy (CTE) or other neurodegenerative disorders, according to a review in the June issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]
Omega-3 fatty acids improve cognitive flexibility in older adults at risk of late-onset Alzheimer's disease

Omega-3 fatty acids improve cognitive flexibility in older adults at risk of late-onset Alzheimer's disease

A study of older adults at risk of late-onset Alzheimer's disease found that those who consumed more omega-3 fatty acids did better than their peers on tests of cognitive flexibility -- the ability to efficiently switch between tasks -- and had a bigger anterior cingulate cortex, a brain region known to contribute to cognitive flexibility. [More]
vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for treatment of mild Alzheimer's disease

vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for treatment of mild Alzheimer's disease

vTv Therapeutics LLC today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer's disease. [More]
Study: Air pollution, impaired lung function independently affect cognition

Study: Air pollution, impaired lung function independently affect cognition

Studies have shown that both air pollution and impaired lung function can cause cognitive deficits, but it was unclear whether air pollution diminishes cognition by reducing breathing ability first or whether air pollution represents an independent risk factor for cognitive deficit. [More]
Grass plants can bind, uptake and transport infectious prions

Grass plants can bind, uptake and transport infectious prions

Grass plants can bind, uptake and transport infectious prions, according to researchers at The University of Texas Health Science Center at Houston (UTHealth). [More]
Research leads way for noninvasive detection of early stage liver cancer

Research leads way for noninvasive detection of early stage liver cancer

Led by Georgia State University, researchers have developed the first robust and noninvasive detection of early stage liver cancer and liver metastases, in addition to other liver diseases, such as cirrhosis and liver fibrosis. [More]
Researchers explore how low-level electrical stimulation reduces inflammation

Researchers explore how low-level electrical stimulation reduces inflammation

The Feinstein Institute for Medical Research, the research arm of the North Shore-LIJ Health System, and SetPoint Medical Inc., a biomedical technology company, today released the results of research on the therapeutic potential of vagus nerve stimulation. In a paper published by Bioelectronic Medicine, Kevin J. Tracey, MD, and his colleagues at the Feinstein Institute, explore how low-level electrical stimulation interacts with the body's nerves to reduce inflammation, a fundamental goal of bioelectronic medicine. [More]
Denali launched to discover, develop effective medicines for neurodegenerative diseases

Denali launched to discover, develop effective medicines for neurodegenerative diseases

Denali Therapeutics Inc., a new biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that it has launched with an initial investment commitment of $217 million. [More]
New work challenges long-held beliefs about link between hippocampus and improved memory function

New work challenges long-held beliefs about link between hippocampus and improved memory function

New work by the Douglas Mental Health University Institute (CIUSSS de l'Ouest-de-l'île-de-MontréalI) computational neuroscientist Mallar Chakravarty, PhD, and in collaboration with researchers at the Centre for Addiction and Mental Health challenges in a thrilling way the long-held belief that a larger hippocampus is directly linked to improved memory function. [More]
Eating Mediterranean diet helps delay cognitive decline

Eating Mediterranean diet helps delay cognitive decline

Professor of Preventive Medicine at the University of Valencia Dolors Corella is part of the multidisciplinary team conducting the Predimed study, which has found that eating a Mediterranean diet, enriched with olive oil or nuts, helps delay cognitive decline. [More]
Repetitive head injuries may accelerate aging process, increase dementia risk

Repetitive head injuries may accelerate aging process, increase dementia risk

Repetitive head injuries that occur during contact sports and military service may accelerate the aging process by increasing the build-up of beta-amyloid in the brain, leading to worse disease and an increased likelihood of developing dementia. In particular, boxers fared the worst among athletes and military veterans with a history of head injuries. [More]
Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

In a major advance in the field of neuropsychiatry, researchers in the Vollum Institute at Oregon Health & Science University have illuminated how cocaine and amphetamines disrupt the normal functioning of the dopamine transporter in the brain. [More]
Knowing the physical structure of amyloid beta-42 offers new view on amyloid propagation in Alzheimer's

Knowing the physical structure of amyloid beta-42 offers new view on amyloid propagation in Alzheimer's

Researchers at the University of Illinois at Chicago have determined the molecular structure of one of the proteins in the fine fibers of the brain plaques that are a hallmark of Alzheimer's disease. This molecule, called amyloid beta-42, is toxic to nerve cells and is believed to provoke the disease cascade. [More]
GTEx findings reveal how genomic variants can affect gene activity and disease susceptibility

GTEx findings reveal how genomic variants can affect gene activity and disease susceptibility

Researchers funded by the National Institutes of Health Genotype-Tissue Expression (GTEx) project have created a new and much-anticipated data resource to help establish how differences in an individual's genomic make-up can affect gene activity and contribute to disease. [More]
NIH-sponsored Phase 1 clinical trial evaluates novel investigational West Nile virus vaccine

NIH-sponsored Phase 1 clinical trial evaluates novel investigational West Nile virus vaccine

A novel investigational West Nile virus vaccine discovered and developed by scientists at the Oregon National Primate Research Center at Oregon Health & Science University is being evaluated in an NIH-sponsored Phase 1, first-in-human, clinical trial at Duke University. Although several early-stage West Nile virus vaccine clinical trials have been completed to date, no human vaccine has been approved for commercial use. [More]
Advertisement
Advertisement